FibroGen, Inc. (FGEN) P/E Ratio History
Historical price-to-earnings valuation from 2019 to 2025
Loading P/E history...
FGEN Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, FibroGen, Inc. (FGEN) trades at a price-to-earnings ratio of -15.6x, with a stock price of $7.50 and trailing twelve-month earnings per share of $53.33.
The current P/E is 101% below its 5-year average of 1608.7x. Over the past five years, FGEN's P/E has ranged from a low of 0.2x to a high of 2455.4x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, FGEN trades at a 170% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, FGEN trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our FGEN DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
FGEN P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $5B | 8.3 | - | +264% | |
| $166B | 19.8 | 0.15Best | +1684%Best | |
| $10B | 30.1 | - | -19% | |
| $2B | 6.9Lowest | 0.67 | +817% | |
| $8B | 25.5 | 1.11 | -25% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
FGEN Historical P/E Data (2019–2025)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q3 | $12.25 | $52.28 | 0.2x | -100% | |
| FY2019 Q3 | Mon Sep 30 2019 00:00:00 GM | $924.50 | $0.39 | 2370.5x | +47% |
| FY2019 Q2 | Sun Jun 30 2019 00:00:00 GM | $1129.50 | $0.46 | 2455.4x | +53% |
Average P/E for displayed period: 1608.7x
See FGEN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs FGEN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare FGEN vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonFGEN — Frequently Asked Questions
Quick answers to the most common questions about buying FGEN stock.
Is FGEN stock overvalued or undervalued?
FGEN trades at -15.6x P/E, below its 5-year average of 1608.7x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does FGEN's valuation compare to peers?
FibroGen, Inc. P/E of -15.6x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is FGEN's PEG ratio?
FGEN PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2019-2025.